Roivant Sciences (NASDAQ:ROIV) CEO Eric Venker Sells 200,000 Shares

Roivant Sciences Ltd. (NASDAQ:ROIV) CEO Eric Venker sold 200,000 shares of the firm’s stock in a transaction that occurred on Wednesday, June 24th. The shares were sold at an average price of $33.16, for a total transaction of $6,632,000.00. Following the completion of the transaction, the chief executive officer owned 1,613,063 shares of the company’s stock, valued at approximately $53,489,169.08. This trade represents a 11.03% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Eric Venker also recently made the following trade(s):

• On Friday, May 22nd, Eric Venker sold 200,000 shares of Roivant Sciences stock. The stock was sold at an average price of $30.27, for a total transaction of $6,054,000.00.
• On Monday, April 20th, Eric Venker sold 200,000 shares of Roivant Sciences stock. The stock was sold at an average price of $29.59, for a total transaction of $5,918,000.00.

Roivant Sciences Stock Performance

Shares of NASDAQ ROIV opened at $34.07 on Friday. Roivant Sciences Ltd. has a 52-week low of $10.70 and a 52-week high of $34.68. The firm has a 50 day moving average price of $29.66 and a two-hundred day moving average price of $26.77. The stock has a market cap of $24.51 billion, a P/E ratio of -56.78 and a beta of 1.13.

Roivant Sciences (NASDAQ:ROIV) last issued its quarterly earnings results on Wednesday, May 20th. The company reported $0.28 EPS for the quarter, topping analysts’ consensus estimates of ($0.29) by $0.57. Roivant Sciences had a negative net margin of 3,629.19% and a negative return on equity of 20.54%. The company had revenue of $2.52 million for the quarter, compared to analyst estimates of $3.41 million. During the same quarter in the previous year, the business earned ($0.29) earnings per share. Analysts predict that Roivant Sciences Ltd. will post -1.83 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Roivant Sciences

Large investors have recently bought and sold shares of the stock. Fifth Third Bancorp raised its holdings in shares of Roivant Sciences by 8.7% during the first quarter. Fifth Third Bancorp now owns 4,686 shares of the company’s stock valued at $130,000 after purchasing an additional 376 shares during the period. Bessemer Group Inc. boosted its position in shares of Roivant Sciences by 21.8% during the 1st quarter. Bessemer Group Inc. now owns 2,465 shares of the company’s stock worth $69,000 after purchasing an additional 441 shares in the last quarter. Fifth Third Wealth Advisors LLC grew its stake in shares of Roivant Sciences by 4.6% in the 1st quarter. Fifth Third Wealth Advisors LLC now owns 10,166 shares of the company’s stock valued at $282,000 after buying an additional 445 shares during the period. Oregon Public Employees Retirement Fund grew its stake in shares of Roivant Sciences by 0.6% in the 4th quarter. Oregon Public Employees Retirement Fund now owns 87,152 shares of the company’s stock valued at $1,891,000 after buying an additional 500 shares during the period. Finally, Bank of Montreal Can grew its stake in shares of Roivant Sciences by 1.3% in the 4th quarter. Bank of Montreal Can now owns 40,012 shares of the company’s stock valued at $868,000 after buying an additional 516 shares during the period. 64.76% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

ROIV has been the topic of several recent research reports. Citigroup lifted their target price on Roivant Sciences from $35.00 to $42.00 and gave the stock a “buy” rating in a report on Thursday, May 21st. HC Wainwright restated a “buy” rating and set a $34.00 price objective on shares of Roivant Sciences in a research report on Thursday, May 21st. TD Cowen lifted their price objective on Roivant Sciences from $38.00 to $41.00 and gave the stock a “buy” rating in a research note on Thursday, May 21st. Jefferies Financial Group reiterated a “buy” rating on shares of Roivant Sciences in a report on Tuesday, March 3rd. Finally, Weiss Ratings downgraded shares of Roivant Sciences from a “sell (d)” rating to a “sell (d-)” rating in a research report on Friday, May 22nd. Ten research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, Roivant Sciences has an average rating of “Moderate Buy” and a consensus target price of $33.59.

Roivant Sciences Company Profile

Roivant Sciences is a biopharmaceutical company focused on the development and commercialization of innovative therapies through a network of subsidiary businesses known as “Vants.” Founded in 2014, Roivant acquires or in-licenses clinical-stage assets that have progressed beyond proof of concept and seeks to advance them efficiently toward regulatory approval. By organizing each program into a dedicated subsidiary, the company aims to streamline decision-making, allocate resources more effectively, and accelerate development timelines.

The core activities of Roivant involve identifying promising drug candidates across a range of therapeutic areas, including neurology, rare diseases, immunology, oncology, and women’s health.